282 related articles for article (PubMed ID: 26279303)
1. PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition.
Meng Z; Jia LF; Gan YH
Oncogene; 2016 May; 35(18):2333-44. PubMed ID: 26279303
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN.
Zhang G; Gan YH
Oncol Rep; 2017 Nov; 38(5):2657-2666. PubMed ID: 29048666
[TBL] [Abstract][Full Text] [Related]
3. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
5. AKT activation controls cell survival in response to HDAC6 inhibition.
Kaliszczak M; Trousil S; Ali T; Aboagye EO
Cell Death Dis; 2016 Jun; 7(6):e2286. PubMed ID: 27362804
[TBL] [Abstract][Full Text] [Related]
6. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth.
Kaliszczak M; Trousil S; Åberg O; Perumal M; Nguyen QD; Aboagye EO
Br J Cancer; 2013 Feb; 108(2):342-50. PubMed ID: 23322205
[TBL] [Abstract][Full Text] [Related]
7. NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells.
Pai JT; Hsu CY; Hua KT; Yu SY; Huang CY; Chen CN; Liao CH; Weng MS
Molecules; 2015 May; 20(5):8000-19. PubMed ID: 25946558
[TBL] [Abstract][Full Text] [Related]
8. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
9. Restoration of mutant hERG stability by inhibition of HDAC6.
Li P; Kurata Y; Endang M; Ninomiya H; Higaki K; Taufiq F; Morikawa K; Shirayoshi Y; Horie M; Hisatome I
J Mol Cell Cardiol; 2018 Feb; 115():158-169. PubMed ID: 29355491
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.
Namdar M; Perez G; Ngo L; Marks PA
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20003-8. PubMed ID: 21037108
[TBL] [Abstract][Full Text] [Related]
11. 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation.
Mahal K; Kahlen P; Biersack B; Schobert R
Exp Cell Res; 2015 Aug; 336(2):263-75. PubMed ID: 26101158
[TBL] [Abstract][Full Text] [Related]
12. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.
Miyake Y; Keusch JJ; Wang L; Saito M; Hess D; Wang X; Melancon BJ; Helquist P; Gut H; Matthias P
Nat Chem Biol; 2016 Sep; 12(9):748-54. PubMed ID: 27454931
[TBL] [Abstract][Full Text] [Related]
13. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
Brush MH; Guardiola A; Connor JH; Yao TP; Shenolikar S
J Biol Chem; 2004 Feb; 279(9):7685-91. PubMed ID: 14670976
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
Wang Q; Tan R; Zhu X; Zhang Y; Tan Z; Su B; Li Y
Oncotarget; 2016 Mar; 7(9):10064-72. PubMed ID: 26848526
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer.
Dhar S; Kumar A; Li K; Tzivion G; Levenson AS
Biochim Biophys Acta; 2015 Feb; 1853(2):265-75. PubMed ID: 25447541
[TBL] [Abstract][Full Text] [Related]
16. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Yang F; Wang F; Liu Y; Wang S; Li X; Huang Y; Xia Y; Cao C
Life Sci; 2018 Nov; 213():149-157. PubMed ID: 30352240
[TBL] [Abstract][Full Text] [Related]
17. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
[TBL] [Abstract][Full Text] [Related]
18. Selective HDAC6 inhibition prevents TNF-α-induced lung endothelial cell barrier disruption and endotoxin-induced pulmonary edema.
Yu J; Ma Z; Shetty S; Ma M; Fu J
Am J Physiol Lung Cell Mol Physiol; 2016 Jul; 311(1):L39-47. PubMed ID: 27190059
[TBL] [Abstract][Full Text] [Related]
19. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
[TBL] [Abstract][Full Text] [Related]
20. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models.
Depetter Y; Geurs S; De Vreese R; Goethals S; Vandoorn E; Laevens A; Steenbrugge J; Meyer E; de Tullio P; Bracke M; D'hooghe M; De Wever O
Int J Cancer; 2019 Aug; 145(3):735-747. PubMed ID: 30694564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
